71 patents
Utility
Methods
4 Jan 24
The present disclosure provides improved conditioning methods for use in hematopoietic stem cell transplantation and hematopoietic stem cell-based gene therapies.
Melissa Bonner, Megan Danielle Hoban
Filed: 5 Nov 21
Utility
Compounds for improved viral transduction
5 Dec 23
The present invention provides methods and compositions for improving efficacy of viral transduction of cells.
Garrett Collins Heffner, Abraham Isaac Bassan
Filed: 17 Dec 20
Utility
Sickled Beta Globin Antibodies
7 Sep 23
The invention provides anti-βS globin antibodies or antigen binding fragments thereof.
Olivier Negre
Filed: 22 Dec 22
Utility
Therapeutic retroviral vectors for gene therapy
18 Jul 23
Provided are improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells.
Philippe Louis Leboulch, Robert Pawliuk, Karen Westerman
Filed: 16 Mar 20
Utility
Sickled beta globin antibodies
27 Dec 22
The invention generally provides improved anti-sickled-globin antibodies and fragments thereof.
Olivier Negre
Filed: 14 Dec 18
Utility
Gene Therapy for Mucopolysaccharidosis, Type I
27 Oct 22
The invention provides compositions and methods for treating MPS I.
Kendrick A. GOSS, Geoffrey B. PARSONS
Filed: 6 Dec 17
Utility
Gene Therapy of Neuronal Ceroid Lipofuscinoses
13 Oct 22
The invention provides, in part, compositions and methods for treating neuronal ceroid lipofuscinoses (NCL).
Kendrick A. GOSS, Geoffrey B. PARSONS, Asiya GINIATULLINA
Filed: 13 Jun 17
Utility
Transduction Efficiency Assay
13 Oct 22
Disclosed herein are lentiviral vector transduction efficiency assays for gene therapy treatments.
Ilya Shestopalov
Filed: 7 Sep 20
Utility
Vectors and Compositions for Treating Hemoglobinopathies
18 Aug 22
The invention provides improved gene therapy vectors, compositions, and methods.
Gabor Veres, David A. Williams
Filed: 28 Jan 22
Utility
Beta-thalassemia Potency Assay
26 May 22
Disclosed herein are potency assays for a gene therapy treatment for β-thalassemia.
ILYA SHESTOPALOV, MELISSA BONNER
Filed: 27 Mar 20
Utility
VCN enhancer compositions and methods of using the same
10 May 22
The invention provides improved gene therapy methods and compositions.
Melissa Bonner, Olivier Negre, Christopher Tipper
Filed: 10 Feb 17
Utility
Vectors and compositions for treating hemoglobinopathies
1 Mar 22
The invention provides improved gene therapy vectors, compositions, and methods.
Gabor Veres, David A. Williams
Filed: 29 Mar 18
Utility
Dimerizing Agent Regulated Immunoreceptor Complexes
3 Feb 22
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, ALEXANDER ASTRAKHAN, WAI-HANG LEUNG
Filed: 13 Dec 19
Utility
Dimerizing Agent Regulated Immunoreceptor Complexes
27 Jan 22
The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, WAI-HANG LEUNG
Filed: 13 Dec 19
Utility
Cell Therapy Vessels
6 Jan 22
The present disclosure provides improved cell therapy vessels, cell therapy vessel adapters, kits, and methods of using the same.
ALDEN LADD
Filed: 6 Nov 19
Utility
CD79A Chimeric Antigen Receptors
26 Aug 21
The invention provides improved compositions for adoptive cell therapies for cancers that express CD79A.
Kevin FRIEDMAN, Molly Reed PERKINS
Filed: 14 Jun 19
Utility
Anti-bcma Car Antibodies, Conjugates, and Methods of Use
26 Aug 21
The invention provides improved methods for detecting anti-BCMA CAR expression on T cells.
Kevin FRIEDMAN, Molly Reed PERKINS
Filed: 14 Jun 19
Utility
Adoptive Cellular Therapy
19 Aug 21
The invention provides improved compositions and methods for the treatment of solid cancers.
James Brian ROTTMAN
Filed: 12 Apr 19
Utility
NKG2D Daric Receptors
5 Aug 21
The present disclosure provides improved compositions for adoptive T cell therapies targeting NKG2D ligands for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, WAI-HANG LEUNG
Filed: 14 Dec 18
Utility
Bruton's Tyrosine Kinase Homing Endonuclease Variants, Compositions, and Methods of Use
29 Jul 21
The present disclosure provides improved genome editing compositions and methods for editing a human BTK gene.
David J. RAWLINGS, Yupeng WANG, Iram F. KHAN, Joel GAY
Filed: 26 Apr 19